Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy

Yoshiya Tanaka, Tsutomu Takeuchi, Nobuyuki Miyasaka, Takayuki Sumida, Tsuneyo Mimori, Takao Koike, Kazuhiro Endo, Naomi Mashino, Kazuhiko Yamamoto

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Objectives. To evaluate the efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus (SLE) and lupus nephritis (LN) who are refractory to conventional immunosuppressive therapy.Methods. Eligible patients received rituximab at a dose of 1,000 mg at days 1, 15, 169, and 183, and were followed for 53 weeks after the first dose of rituximab. Overall disease activity was assessed monthly using a British Isles Lupus Assessment Group activity index. Patients with LN (Upr/Ucr ≥ 1.0 at study entry) were identified and their renal responses were evaluated according to the criteria proposed by the American College of Rheumatology (ACR) and the Lupus Nephritis Assessment with Rituximab (LUNAR) study.Results. A total of 34 patients were enrolled and received at least one dose of rituximab. Decrease in disease activity was achieved in 16 (76.5%) out of 34 patients. In 17 patients with LN, response rates of 58.8% and 52.9% by ACR and LUNAR criteria, respectively, were seen. Successful steroid tapering was achieved in association with disease remission. Rituximab was well tolerated, and most adverse drug reactions were grade 1-2 in severity.Conclusions. Rituximab is effective for treatment of Japanese patients with SLE and LN refractory to conventional therapy.

Original languageEnglish
Pages (from-to)80-86
Number of pages7
JournalModern Rheumatology
Volume26
Issue number1
DOIs
Publication statusPublished - 2016 Jan 2

Fingerprint

Lupus Nephritis
Systemic Lupus Erythematosus
Safety
Therapeutics
Rituximab
Rheumatology
Immunosuppressive Agents
Drug-Related Side Effects and Adverse Reactions
Steroids
Kidney

Keywords

  • Effi cacy
  • Lupus nephritis
  • Phase II study
  • Rituximab
  • Safety

ASJC Scopus subject areas

  • Rheumatology

Cite this

Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy. / Tanaka, Yoshiya; Takeuchi, Tsutomu; Miyasaka, Nobuyuki; Sumida, Takayuki; Mimori, Tsuneyo; Koike, Takao; Endo, Kazuhiro; Mashino, Naomi; Yamamoto, Kazuhiko.

In: Modern Rheumatology, Vol. 26, No. 1, 02.01.2016, p. 80-86.

Research output: Contribution to journalArticle

Tanaka, Yoshiya ; Takeuchi, Tsutomu ; Miyasaka, Nobuyuki ; Sumida, Takayuki ; Mimori, Tsuneyo ; Koike, Takao ; Endo, Kazuhiro ; Mashino, Naomi ; Yamamoto, Kazuhiko. / Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy. In: Modern Rheumatology. 2016 ; Vol. 26, No. 1. pp. 80-86.
@article{a1151a73c95e4982bf11945e4a44d217,
title = "Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy",
abstract = "Objectives. To evaluate the efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus (SLE) and lupus nephritis (LN) who are refractory to conventional immunosuppressive therapy.Methods. Eligible patients received rituximab at a dose of 1,000 mg at days 1, 15, 169, and 183, and were followed for 53 weeks after the first dose of rituximab. Overall disease activity was assessed monthly using a British Isles Lupus Assessment Group activity index. Patients with LN (Upr/Ucr ≥ 1.0 at study entry) were identified and their renal responses were evaluated according to the criteria proposed by the American College of Rheumatology (ACR) and the Lupus Nephritis Assessment with Rituximab (LUNAR) study.Results. A total of 34 patients were enrolled and received at least one dose of rituximab. Decrease in disease activity was achieved in 16 (76.5{\%}) out of 34 patients. In 17 patients with LN, response rates of 58.8{\%} and 52.9{\%} by ACR and LUNAR criteria, respectively, were seen. Successful steroid tapering was achieved in association with disease remission. Rituximab was well tolerated, and most adverse drug reactions were grade 1-2 in severity.Conclusions. Rituximab is effective for treatment of Japanese patients with SLE and LN refractory to conventional therapy.",
keywords = "Effi cacy, Lupus nephritis, Phase II study, Rituximab, Safety",
author = "Yoshiya Tanaka and Tsutomu Takeuchi and Nobuyuki Miyasaka and Takayuki Sumida and Tsuneyo Mimori and Takao Koike and Kazuhiro Endo and Naomi Mashino and Kazuhiko Yamamoto",
year = "2016",
month = "1",
day = "2",
doi = "10.3109/14397595.2015.1060665",
language = "English",
volume = "26",
pages = "80--86",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy

AU - Tanaka, Yoshiya

AU - Takeuchi, Tsutomu

AU - Miyasaka, Nobuyuki

AU - Sumida, Takayuki

AU - Mimori, Tsuneyo

AU - Koike, Takao

AU - Endo, Kazuhiro

AU - Mashino, Naomi

AU - Yamamoto, Kazuhiko

PY - 2016/1/2

Y1 - 2016/1/2

N2 - Objectives. To evaluate the efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus (SLE) and lupus nephritis (LN) who are refractory to conventional immunosuppressive therapy.Methods. Eligible patients received rituximab at a dose of 1,000 mg at days 1, 15, 169, and 183, and were followed for 53 weeks after the first dose of rituximab. Overall disease activity was assessed monthly using a British Isles Lupus Assessment Group activity index. Patients with LN (Upr/Ucr ≥ 1.0 at study entry) were identified and their renal responses were evaluated according to the criteria proposed by the American College of Rheumatology (ACR) and the Lupus Nephritis Assessment with Rituximab (LUNAR) study.Results. A total of 34 patients were enrolled and received at least one dose of rituximab. Decrease in disease activity was achieved in 16 (76.5%) out of 34 patients. In 17 patients with LN, response rates of 58.8% and 52.9% by ACR and LUNAR criteria, respectively, were seen. Successful steroid tapering was achieved in association with disease remission. Rituximab was well tolerated, and most adverse drug reactions were grade 1-2 in severity.Conclusions. Rituximab is effective for treatment of Japanese patients with SLE and LN refractory to conventional therapy.

AB - Objectives. To evaluate the efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus (SLE) and lupus nephritis (LN) who are refractory to conventional immunosuppressive therapy.Methods. Eligible patients received rituximab at a dose of 1,000 mg at days 1, 15, 169, and 183, and were followed for 53 weeks after the first dose of rituximab. Overall disease activity was assessed monthly using a British Isles Lupus Assessment Group activity index. Patients with LN (Upr/Ucr ≥ 1.0 at study entry) were identified and their renal responses were evaluated according to the criteria proposed by the American College of Rheumatology (ACR) and the Lupus Nephritis Assessment with Rituximab (LUNAR) study.Results. A total of 34 patients were enrolled and received at least one dose of rituximab. Decrease in disease activity was achieved in 16 (76.5%) out of 34 patients. In 17 patients with LN, response rates of 58.8% and 52.9% by ACR and LUNAR criteria, respectively, were seen. Successful steroid tapering was achieved in association with disease remission. Rituximab was well tolerated, and most adverse drug reactions were grade 1-2 in severity.Conclusions. Rituximab is effective for treatment of Japanese patients with SLE and LN refractory to conventional therapy.

KW - Effi cacy

KW - Lupus nephritis

KW - Phase II study

KW - Rituximab

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=84952874500&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952874500&partnerID=8YFLogxK

U2 - 10.3109/14397595.2015.1060665

DO - 10.3109/14397595.2015.1060665

M3 - Article

C2 - 26054418

AN - SCOPUS:84952874500

VL - 26

SP - 80

EP - 86

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

IS - 1

ER -